P

Paragon 28 Inc
NYSE:FNA

Watchlist Manager
Paragon 28 Inc
NYSE:FNA
Watchlist
Price: 10.04 USD -3.74% Market Closed
Market Cap: 838.3m USD
Have any thoughts about
Paragon 28 Inc?
Write Note

Paragon 28 Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Paragon 28 Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
P
Paragon 28 Inc
NYSE:FNA
Stock-Based Compensation
$12.4m
CAGR 3-Years
90%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Stock-Based Compensation
$676m
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Paragon 28 Inc
Glance View

Market Cap
839.3m USD
Industry
Health Care

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. The company is headquartered in Englewood, Colorado and currently employs 343 full-time employees. The company went IPO on 2021-10-15. The firm develops, distributes and markets medical devices in the foot and ankle segment of the orthopedic implant marketplace. The firm has developed a range of foot and ankle surgical systems and procedural techniques designed to address the primary conditions requiring treatment in the foot and ankle including fracture fixation, hallux valgus bunions, hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot, and orthobiologics. The products used in foot and ankle procedures include screws, wires and pins, plates, nails, fixators, staples, joint implants, soft tissue implants, orthobiologics and other implantation instruments and disposables. The firm has developed approximately 6,600 implant, 1,200 instrument, and 900 disposable and other stock keeping units (SKU’s). The company has commercial footprint across United States and International.

FNA Intrinsic Value
17.14 USD
Undervaluation 41%
Intrinsic Value
Price
P

See Also

What is Paragon 28 Inc's Stock-Based Compensation?
Stock-Based Compensation
12.4m USD

Based on the financial report for Dec 31, 2023, Paragon 28 Inc's Stock-Based Compensation amounts to 12.4m USD.

What is Paragon 28 Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
90%

Over the last year, the Stock-Based Compensation growth was 19%. The average annual Stock-Based Compensation growth rates for Paragon 28 Inc have been 90% over the past three years .

Back to Top